普乐可复联合护肝片治疗肝移植后轻、中度急性排斥反应的疗效分析

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (11): 1286-1290.

普乐可复联合护肝片治疗肝移植后轻、中度急性排斥反应的疗效分析

张庆¹, 陈虹¹, 张力², 田彦¹, 李勤³, 牛玉坚¹, 陈新国¹, 臧运金¹, 沈中阳¹

¹武警总医院肝移植研究所移植科, 北京 100039;
²武警陕西总队医院外一科,西安 710054, 陕西;
³陕西省肿瘤医院, 西安 710061, 陕西

收稿日期:2008-05-27 修回日期:2008-10-10 出版日期:2008-11-26 发布日期:2020-10-14
通讯作者: 陈虹,女, 医学博士, 主任医师, 硕导, 研究方向:肝移植术后移植物功能异常的诊治。Tel:13501115187 E-mail: ch61520@163.com
作者简介:张庆, 男, 医学博士, 副主任医师, 研究方向:肝移植术后移植物排异反应的诊治。Tel:13426363183 E-mail: zqy6920@yahoo.com.cn

Evaluation of tacrolimus combining with liver-aid tablet in the treatment of acute rejection after liver transplantation

ZHANG Qing¹, CHEN Hong¹, ZHANG Li², TIAN Yan¹, NIU Yu-jian¹, LI Qin³, CHEN Xin-guo¹, ZANG Yun-jin¹, SHEN Zhong-yang¹

¹Instiute of Hepatology Transplantation, General Hospital of Chinese People’ s Armed Police Forces, Beijin 100039, China;
²Department of General Surgery, Shaanxi Provincial Corps Hospital of Chinese People’s Armed Police Forces, Xi’an 710054, Shaanxi, China;
³Department of Radiotherap, Shaanxi Carcinoma Hospital, Xi’an 710061, Shaanxi, China

Received:2008-05-27 Revised:2008-10-10 Online:2008-11-26 Published:2020-10-14

摘要/Abstract

摘要： 目的: 评价普乐可复(FK506) 联合护肝片治疗肝移植后轻、中度急性排斥反应的临床疗效。方法: 将47 例肝移植后出现轻、中度急性排斥反应的移植受者, 分为两组:对照组24 例, 试验组23例。试验组加用护肝片治疗, 3 片/次, 口服, 2 次/d(同FK506 一起服用) 。并于服药后第6 、14 天后复查FK506 血药浓度及肝、肾功能。结果: 试验组加用护肝片后患者的FK506 血药浓度明显提高(P <0.01), 与对照组比较有统计学差异(P <0.01) 。试验组FK506 联合护肝片治疗后的肝功能指标ALT 、AST 、TBIL 、DBIL 均较治疗前明显下降(P <0.01), 和对照组比较差异有统计学意义(P <0.05) 。其中, 试验组治疗后第6 天的显效率达47.83 %, 总有效率达91.30 %, 显著高于对照组(P <0.05) ;治疗后第14 天, 试验组的显效率较对照组提高23.91 %。FK506 联合护肝片治疗对肾功能指标无明显影响。结论: FK506 联合护肝片治疗肝移植后轻、中度急性排斥反应安全、有效。其中, 护肝片不仅可促进肝功能恢复, 还可明显提高FK506 血药浓度, 减少FK506 的用量。

关键词: 肝移植, 急性排斥反应, 护肝片, 普乐可复, 血药浓度, 肝功能

Abstract: AIM: To evaluate the effects of tacrolimus (FK506) combining with liver-aid tablet in treatment of acute rejection after liver transplantation. METHODS: Forty-seven cases with mild to moderate acute rejection after liver transplantation were reviewed, 23 in FK506 combining with liver-aid tablet treatment group, 24 in FK506 without liver-aid tablet control group. Besides treatments with FK506, 23 patients with acute rejection in the treatment group were given liver-aid tablet three pills twice daily. To analyze blood concentration of FK506 biochemically and levels of liver function on the sixth day, fourteenth day after treatments, respectively. RESULTS: The blood concentration of FK506 in the treatment group had a significantly increase as compared with the control group (P <0.01). Liver functions of the patients in the treatment group were improved significantly (P <0.05) on both the sixth day and fourteenth day. Levels of alanine aminotransferase (ALT), aspartate transferase (AST), total bilirubin (TBIL) and direct bilirubin (DBIL) in the treatment group were all significantly lower than those of the control group. The effective rate in treatment group on the 6th day was 47.83 %, and the total effective rate was 91.30 %.Therapeutic effects in the treatment group were significantly better than that in the control group (P < 0.05). CONCLUSION: FK506 combining with liver-aid tablet is safe and effective for the treatment of acute rejection after liver transplantation. Liver-aid tablet is useful not only for promoting liver function, but also for increasing FK506 concentration, as well as for saving money on FK506.

Key words: liver transplantation, acute rejection, liver-aid tablet, tacrolimus, blood concentration, liver function

中图分类号:

R657.3

张庆, 陈虹, 张力, 田彦, 李勤, 牛玉坚, 陈新国, 臧运金, 沈中阳. 普乐可复联合护肝片治疗肝移植后轻、中度急性排斥反应的疗效分析[J]. 中国临床药理学与治疗学, 2008, 13(11): 1286-1290.

ZHANG Qing, CHEN Hong, ZHANG Li, TIAN Yan, NIU Yu-jian, LI Qin, CHEN Xin-guo, ZANG Yun-jin, SHEN Zhong-yang. Evaluation of tacrolimus combining with liver-aid tablet in the treatment of acute rejection after liver transplantation[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(11): 1286-1290.

[1]	余巧玲, 翟葳葳, 刘平, 邱博, 吴惠珍. 利伐沙班血药浓度监测的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 809-817.
[2]	陈以宁, 肖云, 韩晓雨, 黄璐璐, 马景胜, 熊寒斌, 傅毓, 汪保林, 郭晓晖, 钟林, 敖检根, 何佳珂. 肝移植术后排斥合并高血糖的诊治和用药的实践与思考[J]. 中国临床药理学与治疗学, 2023, 28(5): 550-555.
[3]	柳彤, 徐佳明, 王金伙, 尹磊, 陈永权, 郭建荣. 急性等容血液稀释自体血体外隔离期间血浆中麻醉药物浓度变化及回输后对麻醉效应的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 413-418.
[4]	杜文鹏, 敖检根, 陶祎, 吴观胜, 何佳珂. 自身免疫疾病患者他克莫司稳态血药浓度影响因素的研究[J]. 中国临床药理学与治疗学, 2022, 27(6): 645-651.
[5]	胡殷, 杨丹丹, 徐毅超, 邵蓉, 阮邹荣, 江波, 陈金亮, 楼洪刚. 人工神经网络模型在坎地沙坦酯片生物等效性研究中的应用[J]. 中国临床药理学与治疗学, 2022, 27(1): 63-69.
[6]	符祥俊, 黄莉, 郭丽, 林良沫. 万古霉素AUC/MIC在多重耐药革兰阳性菌致重症感染中的应用分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 775-781.
[7]	吴懿, 方芳, 陈瑛, 樊军卫. 供受体CYP3A5基因型对肝移植术后早期他克莫司谷浓度的影响作用及其临床意义[J]. 中国临床药理学与治疗学, 2021, 26(6): 631-639.
[8]	尹磊, 徐佳明, 吴敬医, 段立双, 卫含伟, 金孝岠, 郭建荣. 急性等容血液稀释自体血回输对老年骨科手术患者脑电双谱指数与肌松效应的影响[J]. 中国临床药理学与治疗学, 2021, 26(10): 1153-1158.
[9]	林荣芳, 郑玮玮, 刘亦伟, 林翠鸿, 王长连, 黄品芳. 克罗恩病患者英夫利西单抗相关基因多态性与血药浓度及疗效关联性研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1000-1006.
[10]	王高卿, 江伟, 华永飞. 雷替曲塞联合腹腔镜肝切除术对原发性肝癌患者肝功能及CIART、AFP-L3、GP73的影响[J]. 中国临床药理学与治疗学, 2020, 25(7): 752-756.
[11]	郭明星, 郭恒, 沈素, 孙丽莹, 崔向丽. 肝功能不全患者伏立康唑血药浓度监测回顾性研究[J]. 中国临床药理学与治疗学, 2020, 25(7): 757-763.
[12]	孙青, 孙建芳, 李力, 常会超, 周权. 五酯胶囊对大鼠体内辛伐他汀及其代谢物辛伐他汀酸药代动力学影响[J]. 中国临床药理学与治疗学, 2020, 25(11): 1242-1249.
[13]	吴懿, 王让让, 王兆文, 樊军卫. 受体SLCO1B1 rs2291075位点多态性对肝移植术后早期他克莫司剂量校正谷浓度的影响[J]. 中国临床药理学与治疗学, 2020, 25(11): 1268-1275.
[14]	毛云，张兆瑞. 人参皂苷诱导骨髓间充质干细胞对急性肝功能衰竭大鼠肝组织再生及Wnt/β-catenin信号表达的影响[J]. 中国临床药理学与治疗学, 2019, 24(5): 503-510.
[15]	漆勇，张崧，陆才德. 氨甲环酸联合低中心静脉压在肝移植术中的应用研究[J]. 中国临床药理学与治疗学, 2019, 24(3): 307-312.